Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

FGEN

FibroGen Inc

May 01 • 04:00PM ET

1.17

Dollar change +0.05
Percentage change 4.46	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWM IWN VTWO VHT FESM VTWV IWV BTEC

Index	RUT	P/E	-	EPS (ttm)	-2.93	Insider Own	7.08%	Shs Outstand	98.77M	Perf Week	18.87%
Market Cap	116.38M	Forward P/E	-	EPS next Y	-0.44	Insider Trans	0.72%	Shs Float	92.43M	Perf Month	-45.83%
Income	-284.23M	PEG	-	EPS next Q	-0.42	Inst Own	69.09%	Short Float	5.87%	Perf Quarter	-39.06%
Sales	147.75M	P/S	0.79	EPS this Y	54.53%	Inst Trans	2.89%	Short Ratio	2.39	Perf Half Y	133.21%
Book/sh	-2.07	P/B	-	EPS next Y	67.20%	ROA	-55.00%	Short Interest	5.43M	Perf Year	-92.91%
Cash/sh	2.37	P/C	0.49	EPS next 5Y	-	ROE	-42790.17%	52W Range	0.33 - 19.47	Perf YTD	32.01%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-23.23%	ROI	-	52W High	-93.99%	Beta	0.88
Dividend TTM	-	Quick Ratio	1.33	Sales past 5Y	-2.51%	Gross Margin	87.24%	52W Low	251.04%	ATR (14)	0.18
Dividend Ex-Date	-	Current Ratio	1.52	EPS Y/Y TTM	6.75%	Oper. Margin	-182.20%	RSI (14)	37.86	Volatility	12.28% 15.79%
Employees	486	Debt/Eq	-	Sales Y/Y TTM	4.99%	Profit Margin	-192.37%	Recom	4.00	Target Price	1.50
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	18.88%	Payout	-	Rel Volume	0.48	Prev Close	1.12
Sales Surprise	-30.24%	EPS Surprise	-34.12%	Sales Q/Q	-21.03%	Earnings	May 06 AMC	Avg Volume	2.27M	Price	1.17
SMA20	-8.47%	SMA50	-33.41%	SMA200	-5.48%	Trades		Volume	1,088,317	Change	4.46%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-08-23	Downgrade	BofA Securities	Neutral → Underperform	$4 → $2
Jun-26-23	Downgrade	William Blair	Outperform → Mkt Perform
Jun-26-23	Downgrade	Stifel	Buy → Hold
Jun-26-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jun-26-23	Downgrade	BofA Securities	Buy → Neutral
Jun-02-23	Upgrade	Stifel	Hold → Buy	$23 → $32
Jan-31-23	Upgrade	William Blair	Mkt Perform → Outperform
Jan-26-23	Upgrade	Raymond James	Mkt Perform → Outperform	$35
Jan-05-23	Upgrade	BofA Securities	Neutral → Buy	$18 → $27
Sep-22-21	Downgrade	Goldman	Neutral → Sell	$16 → $11
Aug-20-21	Upgrade	Raymond James	Underperform → Mkt Perform
Jul-16-21	Downgrade	Stifel	Buy → Hold	$55 → $29
Jul-16-21	Downgrade	BofA Securities	Buy → Neutral	$29
Apr-07-21	Downgrade	Mizuho	Buy → Neutral	$72 → $29
Apr-07-21	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-31-21	Upgrade	BofA Securities	Neutral → Buy	$47
Mar-02-21	Downgrade	Jefferies	Buy → Hold	$75 → $45
Feb-01-21	Initiated	H.C. Wainwright	Buy	$58
Oct-26-20	Initiated	Raymond James	Underperform
Jul-10-20	Resumed	Stifel	Buy	$71

Show Previous Ratings

Apr-29-24 07:00AM	FibroGen to Report First Quarter 2024 Financial Results (GlobeNewswire)
Apr-24-24 04:02PM	FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) -8.01%
Apr-03-24 09:32AM	Prostate cancer ADC acquired from Fortis breaks FibroGen's clinical losing streak (FierceBiotech.com) -31.94%
Apr-02-24 05:46PM	FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire) -8.47%
Mar-26-24 07:00AM	FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -7.58%
03:45PM	Loading…
Mar-20-24 03:45PM	3 Nightmare Nasdaq Stocks Not Worth Holding Another Day (InvestorPlace)
Mar-11-24 07:00AM	FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer (GlobeNewswire)
Feb-29-24 08:09AM	FibroGen, Inc. (NASDAQ:FGEN) Q4 2023 Earnings Call Transcript (Insider Monkey) -13.85%
Feb-27-24 09:59AM	Q4 2023 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents) +14.59%
Feb-26-24 05:50PM	FibroGen: Q4 Earnings Snapshot (Associated Press Finance)
04:40PM	FibroGen Inc (FGEN) Reports Modest Revenue Growth and Reduced Net Loss in FY 2023 (GuruFocus.com)
04:34PM	UPDATE 1-FibroGen regains rights to anemia drug from AstraZeneca (Reuters)
04:15PM	FibroGen regains rights to anemia drug from AstraZeneca (Reuters)
04:06PM	FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
04:05PM	FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea (GlobeNewswire)
07:00AM	Loading…
Feb-20-24 07:00AM	FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) -17.81%
Feb-05-24 07:00AM	FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024 (GlobeNewswire) +8.87%
Jan-25-24 07:00AM	FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network's Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer (GlobeNewswire) +13.37%
Dec-09-23 05:02PM	FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting (GlobeNewswire)
Nov-07-23 11:01AM	FibroGen, Inc. (NASDAQ:FGEN) Q3 2023 Earnings Call Transcript (Insider Monkey)
10:01AM	Q3 2023 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-06-23 05:33PM	FibroGen Inc (FGEN) Reports 155% YoY Increase in Q3 2023 Net Revenue (GuruFocus.com) -13.62%
05:30PM	FibroGen (FGEN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
04:10PM	FibroGen: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	FibroGen Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-23-23 07:00AM	FibroGen to Report Third Quarter 2023 Financial Results (GlobeNewswire) -7.77%
Aug-31-23 10:15AM	Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More (Zacks)
Aug-30-23 11:09AM	FibroGen (FGEN) Fails to Meet Goals in DMD Study, Stock Down 23% (Zacks) -24.23%
Aug-29-23 06:00PM	FibroGen's drug misses mark on yet another clinical trial (American City Business Journals)
04:15PM	FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy (GlobeNewswire)
09:35AM	Loading…
Aug-16-23 09:35AM	Down -46.88% in 4 Weeks, Here's Why FibroGen (FGEN) Looks Ripe for a Turnaround (Zacks)
Aug-09-23 09:14AM	Is There An Opportunity With FibroGen, Inc.'s (NASDAQ:FGEN) 42% Undervaluation? (Simply Wall St.)
Aug-08-23 10:08AM	Q2 2023 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents) -18.64%
08:59AM	FibroGen, Inc. (NASDAQ:FGEN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-07-23 07:30PM	FibroGen (FGEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) -7.33%
05:40PM	FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:26PM	FibroGen: Q2 Earnings Snapshot (AP Finance)
04:01PM	FibroGen Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-31-23 09:00AM	FibroGen limits rare-disease drug's access after clinical trial failure. Some parents say it was saving their kids' lives (American City Business Journals) +7.29%
Jul-25-23 10:49AM	FibroGen CEO resigns after back-to-back drug study failures, job cuts (American City Business Journals) -5.74%
07:00AM	FibroGen Announces Leadership Transition (GlobeNewswire)
Jul-24-23 07:00AM	FibroGen to Report Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-21-23 07:17AM	Eliem (ELYM) to Explore Strategic Options, Stock Rises 6% (Zacks) -5.41%
Jul-19-23 10:50AM	Pioneering Mission Bay biotech company Fibrogen to cut more than 100 jobs (American City Business Journals) -7.03%
Jul-14-23 09:55AM	FibroGen (FGEN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Jul-11-23 09:35AM	Down -83.78% in 4 Weeks, Here's Why FibroGen (FGEN) Looks Ripe for a Turnaround (Zacks)
Jul-01-23 08:46AM	Down 80% in 1 Day, Is There Any Hope for FibroGen Stock? (Motley Fool)
Jun-27-23 12:45PM	FibroGen (FGEN) Plunges on Failure of Late-Stage IPF Study (Zacks) -7.38%
Jun-26-23 04:04PM	FibroGen Crashes To Its Lowest-Ever Point On A Second Failure For Its Lead Drug (Investor's Business Daily) -83.12%
11:34AM	FibroGen, Inc.'s (NASDAQ:FGEN) institutional investors lost 4.0% last week but have benefitted from longer-term gains (Simply Wall St.)
07:22AM	UPDATE 2-FibroGen's drug fails late-stage trial for treating lung disease (Reuters)
07:11AM	FibroGen's lung disease treatment fails in late-stage trial (Reuters)
07:04AM	FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Jun-08-23 01:03PM	FibroGen (FGEN) Pamrevlumab Fails DMD Study, Stock Down 8% (Zacks)
Jun-07-23 04:03PM	FibroGen Stock Plunges Under Key Lines As Lead Drug Fails; Why Hope Isn't Lost (Investor's Business Daily) -8.44%
11:47AM	FibroGen's One Study For Duchenne Muscular Dystrophy Fails To Hit Main Goal (Benzinga)
07:02AM	FibroGen's neuromuscular disease drug fails to meet main goal in late-stage study (Reuters)
06:55AM	FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy (GlobeNewswire)
Jun-06-23 04:01PM	FibroGen to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
02:06PM	FibroGen Stock Joins Rank Of Stocks With RS Ratings Over 90 (Investor's Business Daily)
May-18-23 07:30AM	FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia (GlobeNewswire)
May-09-23 10:22AM	Q1 2023 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents)
May-08-23 05:15PM	FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:12PM	FibroGen: Q1 Earnings Snapshot (AP Finance)
04:01PM	FibroGen Reports First Quarter 2023 Financial Results (GlobeNewswire)
04:00PM	FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics (GlobeNewswire)
May-05-23 01:19PM	FibroGen, Inc. (NASDAQ:FGEN) Investors Are Less Pessimistic Than Expected (Simply Wall St.)
07:37AM	FibroGen's anemia drug fails to meet main goal in late-stage trial (Reuters)
07:30AM	FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS) (GlobeNewswire)
May-03-23 03:43AM	ProPhase Labs, Inc. (PRPH) Surges 8.5%: Is This an Indication of Further Gains? (Zacks)
May-01-23 07:00AM	FibroGen Announces Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value (GlobeNewswire)
Apr-24-23 07:00AM	FibroGen to Report First Quarter 2023 Financial Results (GlobeNewswire) -17.21%
Apr-03-23 07:00AM	FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Mar-24-23 10:21AM	FibroGen (NASDAQ:FGEN investor five-year losses grow to 60% as the stock sheds US$145m this past week (Simply Wall St.)
Mar-11-23 03:27AM	FibroGen, Inc. (NASDAQ:FGEN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Feb-28-23 02:43PM	Q4 2022 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-23 05:25PM	FibroGen (FGEN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
07:00AM	FibroGen to Present at Cowens 43rd Annual Health Care Conference (GlobeNewswire)
Feb-23-23 11:33AM	Should You Buy FibroGen (FGEN) Ahead of Earnings? (Zacks)
07:46AM	4 Drug, Biotech Stocks Poised to Beat Q4 Earnings Estimates (Zacks)
Feb-22-23 10:00AM	Analysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-20-23 10:00AM	FibroGen (FGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-17-23 07:00AM	FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-02-23 07:00AM	FibroGen to Present at SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-16-23 09:34AM	With 73% ownership in FibroGen, Inc. (NASDAQ:FGEN), institutional investors have a lot riding on the business (Simply Wall St.)
Nov-28-22 07:00AM	FibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual Conference (GlobeNewswire)
Nov-09-22 05:15AM	FibroGen Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.) +6.78%
Nov-07-22 05:45PM	FibroGen (FGEN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:01PM	FibroGen Reports Third Quarter 2022 Financial Results (GlobeNewswire)
04:00PM	FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management (GlobeNewswire)
Nov-01-22 07:00AM	FibroGen to Participate at Stifel 2022 Healthcare Conference (GlobeNewswire) +7.06%
Oct-31-22 10:00AM	Earnings Preview: FibroGen (FGEN) Q3 Earnings Expected to Decline (Zacks)
Oct-24-22 07:00AM	FibroGen to Report Third Quarter 2022 Financial Results (GlobeNewswire) +6.46%
Oct-15-22 09:59AM	FibroGen (NASDAQ:FGEN) adds US$108m to market cap in the past 7 days, though investors from five years ago are still down 71% (Simply Wall St.)
Sep-23-22 07:30AM	7 Unknown Biotech Stocks That Could Rocket in 2023 (InvestorPlace)
Aug-26-22 07:00AM	FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS) (GlobeNewswire)
Aug-09-22 06:30AM	How Much Of FibroGen, Inc. (NASDAQ:FGEN) Do Institutions Own? (Simply Wall St.)
Aug-08-22 05:35PM	FibroGen (FGEN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:01PM	FibroGen Reports Second Quarter 2022 Financial Results (GlobeNewswire)

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wettig Thane	CEO	Mar 07 '24	Buy	1.91	50,000	95,470	470,178	Mar 11 07:06 PM
Henderson Jeffrey William	Director	Sep 01 '23	Sale	1.03	2,000	2,060	28,866	Sep 06 08:54 PM
Henderson Jeffrey William	Director	Aug 04 '23	Sale	1.91	2,000	3,820	30,866	Aug 08 07:10 PM
Henderson Jeffrey William	Director	Jul 11 '23	Sale	2.69	2,000	5,380	32,866	Jul 13 08:28 PM
Conterno Enrique A	Chief Executive Officer	Jul 07 '23	Sale	2.80	1,880	5,264	374,722	Jul 10 07:36 PM
Wettig Thane	Chief Commercial Officer	Jun 23 '23	Sale	16.53	791	13,075	108,261	Jun 26 04:27 PM
Chung Christine	SVP, China Operations	Jun 14 '23	Sale	16.79	6,250	104,925	236,327	Jun 15 08:17 PM
Chung Christine	SVP, China Operations	Jun 13 '23	Sale	17.60	6,250	110,000	242,577	Jun 15 08:17 PM
Blaug Suzanne	Director	Jun 09 '23	Sale	17.20	8,520	146,571	29,594	Jun 09 07:54 PM
EDWARDS JEFFREY L	Director	Jun 09 '23	Sale	17.19	7,889	135,622	33,977	Jun 09 07:53 PM
Brennan Aoife	Director	Jun 09 '23	Sale	17.19	4,733	81,367	27,947	Jun 09 07:55 PM
Cravatt Benjamin	Director	Jun 09 '23	Sale	17.17	3,944	67,717	28,736	Jun 09 07:56 PM
Ho Maykin	Director	Jun 08 '23	Sale	17.44	8,520	148,591	31,501	Jun 09 07:54 PM
Henderson Jeffrey William	Director	Jun 08 '23	Sale	17.46	7,000	122,185	34,866	Jun 09 07:52 PM
Conterno Enrique A	Chief Executive Officer	Jun 07 '23	Sale	17.04	8,897	151,583	376,602	Jun 09 07:10 PM
Schoeneck James A	Director	Jun 07 '23	Sale	18.03	7,100	127,987	73,722	Jun 09 07:51 PM
Chung Christine	SVP, China Operations	Jun 07 '23	Sale	17.04	3,633	61,894	248,827	Jun 09 07:38 PM
Eisner Mark	EVP, Chief Medical Officer	Jun 07 '23	Sale	17.04	2,042	34,792	162,862	Jun 09 07:12 PM
Graham Juan	Chief Financial Officer	Jun 07 '23	Sale	16.99	1,785	30,320	71,083	Jun 09 07:39 PM
Wettig Thane	Chief Commercial Officer	Jun 07 '23	Sale	17.04	1,758	29,951	111,395	Jun 09 07:39 PM
Eisner Mark	EVP, Chief Medical Officer	Jun 02 '23	Sale	18.83	1,090	20,525	164,904	Jun 05 04:22 PM

Open in Screener

LLY

Lilly(Eli) & Co

May 01 • 04:00PM ET

776.75

Dollar change -4.35
Percentage change -0.56	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VOO IVV VUG IWF VHT QUAL IVW VV SCHG

Index	S&P 500	P/E	116.33	EPS (ttm)	6.68	Insider Own	10.62%	Shs Outstand	949.38M	Perf Week	6.08%
Market Cap	738.51B	Forward P/E	41.82	EPS next Y	18.57	Insider Trans	-0.86%	Shs Float	849.83M	Perf Month	1.67%
Income	6.14B	PEG	2.30	EPS next Q	2.76	Inst Own	73.54%	Short Float	0.65%	Perf Quarter	20.31%
Sales	35.93B	P/S	20.55	EPS this Y	111.00%	Inst Trans	0.66%	Short Ratio	1.76	Perf Half Y	37.31%
Book/sh	11.35	P/B	68.46	EPS next Y	39.29%	ROA	9.23%	Short Interest	5.54M	Perf Year	91.41%
Cash/sh	3.08	P/C	252.25	EPS next 5Y	50.67%	ROE	48.93%	52W Range	392.26 - 800.78	Perf YTD	33.25%
Dividend Est.	5.28 (0.68%)	P/FCF	931.87	EPS past 5Y	13.74%	ROI	21.10%	52W High	-3.00%	Beta	0.37
Dividend TTM	4.69 (0.60%)	Quick Ratio	0.73	Sales past 5Y	9.91%	Gross Margin	83.79%	52W Low	98.02%	ATR (14)	19.75
Dividend Ex-Date	Feb 14, 2024	Current Ratio	0.94	EPS Y/Y TTM	-16.43%	Oper. Margin	31.58%	RSI (14)	59.10	Volatility	2.13% 2.37%
Employees	43000	Debt/Eq	2.34	Sales Y/Y TTM	29.76%	Profit Margin	17.08%	Recom	1.69	Target Price	850.95
Option/Short	Yes / Yes	LT Debt/Eq	1.70	EPS Q/Q	66.67%	Payout	77.91%	Rel Volume	0.88	Prev Close	781.10
Sales Surprise	-1.88%	EPS Surprise	4.64%	Sales Q/Q	25.98%	Earnings	Apr 30 BMO	Avg Volume	3.14M	Price	776.75
SMA20	3.27%	SMA50	2.08%	SMA200	24.13%	Trades		Volume	2,762,819	Change	-0.56%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-21-24	Downgrade	DZ Bank	Buy → Hold	$820
Feb-16-24	Reiterated	Morgan Stanley	Overweight	$805 → $950
Dec-21-23	Downgrade	Daiwa Securities	Buy → Outperform	$660 → $610
Nov-09-23	Initiated	Deutsche Bank	Hold	$535
Oct-20-23	Resumed	UBS	Buy	$612 → $710
Aug-09-23	Upgrade	Jefferies	Hold → Buy	$408 → $615
Jul-26-23	Reiterated	Citigroup	Buy	$360 → $525
Jul-14-23	Initiated	HSBC Securities	Buy	$560
May-24-23	Reiterated	UBS	Buy	$447 → $498
May-24-23	Reiterated	BofA Securities	Buy	$450 → $500
Mar-13-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$360 → $375
Mar-06-23	Initiated	Jefferies	Hold	$290
Feb-15-23	Downgrade	Societe Generale	Hold → Sell
Nov-18-22	Initiated	Credit Suisse	Outperform	$395
Sep-22-22	Upgrade	UBS	Neutral → Buy	$335 → $363
May-23-22	Initiated	SVB Leerink	Outperform	$341
Apr-06-22	Resumed	Morgan Stanley	Overweight	$265 → $364
Mar-10-22	Initiated	Daiwa Securities	Outperform	$286
Jan-21-22	Upgrade	DZ Bank	Hold → Buy	$291
Jan-03-22	Reiterated	Bernstein	Mkt Perform	$250 → $300

Show Previous Ratings

May-01-24 03:36PM	Q1 Earnings Seasons Picks & Pans: The 4 Biggest Stock Winners (and 3 Losers) (InvestorPlace)
02:19PM	Trade Tracker: Joe Terranova sells Eli Lilly (CNBC TV)
01:41PM	Profit from the Panic: 3 Stocks to Pounce on When They Become Steals (InvestorPlace)
12:38PM	Stock Market Crash Warning: Don't Get Caught Holding These 3 Consumer Stocks. (InvestorPlace)
11:59AM	Stock Market Crash Alert: 3 Must-Buy Biotech Stocks When Prices Plunge (InvestorPlace)
11:36AM	Loading…
11:36AM	Danish Medicines Agency Says Type 2 Diabetes Patients Should Start Treatment With 'Cheaper' Drugs (MT Newswires)
10:47AM	3 Healthcare Stocks With the Potential to Triple Your Investment by 2026 (InvestorPlace)
10:32AM	Amazon, AMD, and Super Micro Sing the Same Sad Song, and 5 Other Things to Know Before Markets Open. (Barrons.com)
10:26AM	JPMorgan Adjusts Price Target on Eli Lilly to $900 From $850 (MT Newswires)
09:57AM	Wolfe Research Adjusts Price Target on Eli Lilly to $909 From $813 (MT Newswires)
08:30AM	Barclays Adjusts Price Target on Eli Lilly and Company to $913 From $810 (MT Newswires)
08:21AM	BMO Capital Adjusts Eli Lilly Price Target to $1,001 From $900 (MT Newswires)
08:10AM	Leerink Partners Adjusts Price Target on Eli Lilly to $901 From $821 (MT Newswires)
07:51AM	Deutsche Bank Adjusts Price Target on Eli Lilly to $725 From $695 (MT Newswires)
07:37AM	Truist Raises Price Target on Eli Lilly to $892 From $850, Keeps Buy Rating (MT Newswires)
07:35AM	Loading…
07:35AM	Goldman Sachs Adjusts Price Target on Eli Lilly to $740 From $723 (MT Newswires)
07:27AM	Wells Fargo Adjusts Eli Lilly Price Target to $875 From $825 (MT Newswires)
07:06AM	Amazon, AMD, Super Micro Earnings Tell Investors the Same Thing, Its Bad News. And 5 Other Things to Know Before Markets Open. (Barrons.com)
06:27AM	Morgan Stanley Raises Price Target on Eli Lilly to $1,023 From $950 Amid 2024 Guidance Boost, Keeps Overweight Rating (MT Newswires)
06:00AM	3 stocks with the biggest gains took April's biggest losses (Yahoo Finance)
03:25AM	Q1 2024 Eli Lilly and Co Earnings Call (Thomson Reuters StreetEvents)
03:17AM	Eli Lilly and Co (LLY) Q1 2024 Earnings Call Transcript Highlights: Stellar Growth and ... (GuruFocus.com)
02:00AM	This Options-Backed Strategy Can Help You Dodge the Stock Markets Hazards (Barrons.com)
01:01AM	Decoding Eli Lilly and Co (LLY): A Strategic SWOT Insight (GuruFocus.com)
Apr-30-24 05:23PM	IBD Stock Of The Day Eli Lilly Surges After Weight-Loss Drug Obliterates Sales Views (Investor's Business Daily) +5.95%
05:14PM	REFILE-CORRECTED-US STOCKS-Wall Street stocks fall as markets weigh strong wage data, Fed meeting (Reuters)
04:41PM	S&P 500 Gains and Losses Today: GE HealthCare Stock Plunges After Earnings Miss (Investopedia)
04:39PM	US STOCKS-Wall Street ends lower as markets weigh strong wage data, Fed meeting (Reuters)
04:38PM	Stocks End April On Sour Note, Dow Loses 570 Points (Investor's Business Daily)
04:05PM	US Equity Markets Close Down Tuesday After Higher Wage Data (MT Newswires)
04:00PM	Loading…
04:00PM	CORRECTED-US STOCKS-Wall Street stocks fall as markets weigh strong wage data, Fed meeting (Reuters)
03:58PM	Sector Update: Health Care Stocks Mixed Late Afternoon (MT Newswires)
03:22PM	Stocks At Day's Lows; Dow Loses 400 Points, These Stocks Flash Sell Signals (Investor's Business Daily)
03:22PM	Stocks At Day's Lows As Dow Loses 400 Points; These Stocks Flash Sell Signals (Investor's Business Daily)
02:49PM	US STOCKS-Wall Street stocks fall as markets weigh strong wage data, Fed meeting (Reuters)
02:30PM	Eli Lilly (LLY) Q1 2024 Earnings Call Transcript (Motley Fool)
02:00PM	Stocks Keep Sinking, With Dow Losing 300 Points; IBD 50 Stock Hubbell Plunges (Investor's Business Daily)
01:59PM	Taxpayer to fork out £85bn to cover Bank of England losses (The Telegraph)
01:55PM	Sector Update: Health Care Stocks Gain in Afternoon Trading (MT Newswires)
01:40PM	Sector Update: Health Care (MT Newswires)
01:23PM	Eli Lilly reports $2 billion from Mounjaro, Zepbound in Q1 2024 (Yahoo Finance)
01:04PM	Potential for Weight-Loss Drugs Boosts Eli Lilly (Bloomberg)
12:56PM	Top Stock Movers Now: Eli Lilly, GE HealthCare, 3M, and More (Investopedia)
12:44PM	Analyst Report: Eli Lilly and Company (Morningstar Research)
12:26PM	Lilly Soars as Forecast Boost Shows Weight-Loss Drugs Power (Bloomberg)
12:22PM	Eli Lilly, 3M rise; MicroStrategy, Chegg fall, Tuesday, 4/30/2024 (Associated Press)
12:22PM	Stocks Weaken With Dow Sinking 300 Points; PayPal Breaks Out But Fades (Investor's Business Daily)
11:59AM	Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings (MT Newswires)
11:54AM	Jefferies Adjusts Eli Lilly and Co.'s Price Target to $915 From $895, Keeps Buy Rating (MT Newswires)
11:49AM	Weight loss drugs are so hot that Eli Lilly is expecting $2 billion more in sales this year (Quartz)
11:45AM	Eli Lilly (LLY) Q1 Earnings Top, Sales Miss, 2024 View Raised (Zacks)
11:41AM	Eli Lilly's Weight-Loss Drug Still Going Strong, Boosts Annual Forecast (Benzinga)
11:38AM	US STOCKS-Wall St falls on hot labor costs data, caution before Fed verdict (Reuters)
11:26AM	Why Eli Lilly Stock Is Jumping Today (Motley Fool)
11:15AM	Is Eli Lilly Stock A Buy After Weight-Loss Drug Crushes Quarterly Sales Forecasts? (Investor's Business Daily)
11:06AM	Eli Lilly stock jumps on weight-loss drug sales forecast (Yahoo Finance Video)
10:53AM	LLY Stock Earnings: Eli Lilly Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
10:44AM	Stocks Retreat With Dow Hit Hardest; Tesla Drops As Executives Get Sacked (Investor's Business Daily)
10:40AM	Eli Lilly's GLP-1 demand drives up stock price post Q1 results (Yahoo Finance Video)
10:21AM	US STOCKS-Wall St falls in lead up to Fed verdict after hot labor costs data (Reuters)
10:12AM	Eli Lilly is a 'multi-diversified drugmaker', says Cantor Fitzgerald's Louise Chen (CNBC TV)
10:05AM	Eli Lilly Stock Surges as Weight-Loss Drugs Continue to Fuel Growth (Investopedia)
09:56AM	Eli Lilly Surges On Guidance Boost After Weight-Loss Drug Obliterates Sales Views (Investor's Business Daily)
09:55AM	Stocks to Watch Tuesday: PayPal, Eli Lilly, 3M, McDonald's (The Wall Street Journal)
09:30AM	Lilly (LLY) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
09:20AM	Sector Update: Health Care Stocks Mixed Premarket Tuesday (MT Newswires)
09:11AM	Eli Lilly CEO on weight loss drugs outlook: Our top priority is making more product (CNBC TV)
09:08AM	US STOCKS-Wall St set to open lower on economic data; Fed verdict on tap (Reuters)
09:04AM	Lilly rides Mounjaro, Zepbound to better-than-expected 1Q profit despite supply issues (Associated Press Finance)
08:43AM	Eli Lilly Raises 2024 Guidance Following Robust First-Quarter Sales of Diabetes, Weight-Loss Drugs (MT Newswires)
08:32AM	Eli Lilly and Co (LLY) Surpasses Q1 Earnings Estimates and Raises Full-Year Guidance (GuruFocus.com)
07:55AM	Eli Lilly (LLY) Tops Q1 Earnings Estimates (Zacks)
07:54AM	Top Premarket Gainers (MT Newswires)
07:44AM	Eli Lilly Stock Jumps On Strong Earnings, Guidance As Zepbound Sales Easily Beat (Investor's Business Daily)
07:29AM	US STOCKS-Futures drift lower as focus turns to upcoming Fed meet (Reuters)
07:14AM	Eli Lilly's Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Lifted (MT Newswires)
07:12AM	Eli Lilly Stock Jumps After Earnings Beat. Weight-Loss Drugs Are Driving Gains. (Barrons.com)
07:02AM	Eli Lilly Boosts FY24 Outlook - Update (RTT News)
06:53AM	Lilly: Q1 Earnings Snapshot (Associated Press Finance)
06:50AM	Eli Lilly lifts sales view by $2 billion on soaring weight-loss drug demand (Reuters)
06:46AM	Eli Lilly beats profit estimates on diabetes and weight-loss drug strength (Reuters)
06:45AM	Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum (PR Newswire)
02:00AM	Chasing Novo and Lilly: The obesity drugs that could challenge Wegovy and Zepbound (BioPharma Dive)
Apr-29-24 10:09PM	Earnings Exchange: McDonald's, Brinker International, Eli Lilly (CNBC TV)
05:04PM	Why these analysts are bullish on healthcare stocks (Yahoo Finance Video)
04:35PM	All Eyes Are on Zepbound Sales as Lilly Reports Earnings (Barrons.com)
03:35PM	How expanded use of GLP-1s could affect long-term outlooks for Eli Lilly and Novo Nordisk (Yahoo Finance)
12:12PM	UPDATE 2-One dose of Novo Nordisk's Wegovy back in supply, FDA website shows (Reuters)
10:32AM	How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q1 Earnings Report (Benzinga)
10:15AM	Here's How Much Stock Eli Lilly Repurchased in 2023 (Motley Fool)
10:00AM	Novo Nordisk: Growth Is Still A Better Choice (GuruFocus.com)
04:01AM	Pipeline Moves: Investigator-led trial of Lillys merestinib in solid tumours terminated (Clinical Trials Arena)
Apr-28-24 06:20PM	25 States That Are Struggling the Most with Credit Card Debt (Insider Monkey)
01:17PM	Eli Lilly Just Announced More Good News: Time to Buy? (Motley Fool)
08:00AM	What To Expect in the Markets This Week (Investopedia)
Apr-27-24 11:10AM	Forget Nvidia, These Unstoppable Stocks Are Better Buys (Motley Fool)
09:44AM	30 Most Miserable Countries in the World (Insider Monkey)
09:15AM	1 Unstoppable Pharmaceutical Stock Investors Shouldn't Sleep On (Motley Fool)
08:54AM	Goldman Sachs' Top 15 Stock Picks for 2024 (Insider Monkey)
07:15AM	3 Dividend Stocks to Buy and Hold for the Next Decade (Motley Fool)

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zakrowski Donald A	SVP, Finance, & CAO	Mar 11 '24	Sale	753.60	750	565,200	7,880	Mar 11 04:27 PM
LILLY ENDOWMENT INC	10% Owner	Feb 16 '24	Sale	780.99	169,684	132,521,930	98,898,810	Feb 20 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Feb 15 '24	Sale	760.46	50,316	38,263,417	99,068,494	Feb 16 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Feb 09 '24	Sale	740.60	206,257	152,753,428	99,118,810	Feb 12 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Feb 08 '24	Sale	740.06	8,743	6,470,336	99,325,067	Feb 09 04:05 PM
Van Naarden Jacob	EVP & Pres., Loxo@Lilly	Feb 01 '24	Option Exercise	0.00	3,618	0	15,463	Feb 02 04:22 PM
White Anne E.	EVP & Pres, Lilly Neuroscience	Feb 01 '24	Option Exercise	0.00	4,124	0	62,050	Feb 02 04:20 PM
Skovronsky Daniel	EVP, CSO & Pres. LRL & LLY Imm	Feb 01 '24	Option Exercise	0.00	9,941	0	115,262	Feb 02 04:25 PM
Norton Johna	EVP, Global Quality	Feb 01 '24	Option Exercise	0.00	1,268	0	31,382	Feb 02 04:24 PM
Hakim Anat	EVP, GC & Secretary	Feb 01 '24	Option Exercise	0.00	4,442	0	26,631	Feb 02 04:32 PM
Ricks David A	President, Chair, and CEO	Feb 01 '24	Option Exercise	0.00	29,611	0	455,054	Feb 02 04:28 PM
Yuffa Ilya	EVP & President, LLY Int'l	Feb 01 '24	Option Exercise	0.00	3,702	0	16,676	Feb 02 04:29 PM
Jonsson Patrik	EVP&Pres, LLY Dia&Obe, LLY USA	Feb 01 '24	Option Exercise	0.00	4,124	0	41,065	Feb 02 04:26 PM
LILLY ENDOWMENT INC	10% Owner	Jan 31 '24	Sale	648.07	78,573	50,920,924	99,333,810	Feb 01 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jan 30 '24	Sale	645.22	76,215	49,175,200	99,412,383	Jan 31 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Jan 29 '24	Sale	645.07	54,032	34,854,422	99,488,598	Jan 30 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Jan 16 '24	Sale	645.60	1,180	761,806	99,542,630	Jan 17 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Jan 11 '24	Sale	634.13	12,344	7,827,686	99,543,810	Jan 12 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Jan 10 '24	Sale	630.59	163,730	103,246,373	99,556,154	Jan 11 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Jan 09 '24	Sale	631.81	34,538	21,821,413	99,719,884	Jan 10 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jan 04 '24	Sale	630.28	14,388	9,068,445	99,754,422	Jan 05 02:15 PM
Zakrowski Donald A	SVP, Finance, & CAO	Dec 01 '23	Option Exercise	0.00	4,810	0	9,518	Dec 04 04:17 PM
Zakrowski Donald A	SVP, Finance, & CAO	Nov 06 '23	Sale	571.10	670	382,637	4,708	Nov 06 04:25 PM
LILLY ENDOWMENT INC	10% Owner	Oct 11 '23	Sale	605.44	215,000	130,169,879	99,768,810	Oct 12 04:00 PM
Weems Alonzo	EVP, ERM & CECO	Sep 12 '23	Sale	590.98	1,148	678,445	7,760	Sep 13 04:14 PM
LILLY ENDOWMENT INC	10% Owner	Sep 07 '23	Sale	571.41	210,000	119,995,275	99,983,810	Sep 08 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Aug 31 '23	Sale	554.81	46,541	25,821,607	100,193,810	Sep 01 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Aug 30 '23	Sale	555.32	6,181	3,432,417	100,240,351	Aug 31 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Aug 29 '23	Sale	554.10	28,747	15,928,697	100,246,532	Aug 30 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Aug 28 '23	Sale	554.12	37,660	20,868,163	100,275,279	Aug 29 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Aug 25 '23	Sale	554.38	63,572	35,243,238	100,312,939	Aug 28 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Aug 24 '23	Sale	554.74	20,992	11,645,029	100,376,511	Aug 25 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Aug 23 '23	Sale	555.69	1,307	726,284	100,397,503	Aug 24 04:00 PM
Zakrowski Donald A	SVP, Finance, & CAO	Aug 21 '23	Sale	546.51	600	327,906	5,378	Aug 22 04:34 PM
LILLY ENDOWMENT INC	10% Owner	Aug 15 '23	Sale	543.72	50,222	27,306,747	100,398,810	Aug 16 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Aug 14 '23	Sale	539.08	164,778	88,829,243	100,449,032	Aug 15 04:00 PM
ELI LILLY & Co	10% Owner	Aug 11 '23	Buy	14.92	1,718,493	25,639,916	100	Aug 14 04:30 PM
LILLY ENDOWMENT INC	10% Owner	Aug 11 '23	Sale	528.50	83,039	43,886,430	100,613,810	Aug 14 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Aug 10 '23	Sale	528.13	3,000	1,584,405	100,696,849	Aug 11 03:50 PM
LILLY ENDOWMENT INC	10% Owner	Aug 09 '23	Sale	528.83	123,961	65,554,314	100,699,849	Aug 10 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Aug 08 '23	Sale	523.74	204,409	107,056,405	100,823,810	Aug 09 05:10 PM
LILLY ENDOWMENT INC	10% Owner	Jul 21 '23	Sale	466.62	591	275,773	101,028,219	Jul 24 03:55 PM
LILLY ENDOWMENT INC	10% Owner	Jun 30 '23	Sale	467.60	164,125	76,744,390	101,028,810	Jul 03 12:00 PM
LILLY ENDOWMENT INC	10% Owner	Jun 29 '23	Sale	465.08	44,115	20,517,137	101,192,935	Jun 30 03:00 PM
LILLY ENDOWMENT INC	10% Owner	Jun 28 '23	Sale	465.41	11,760	5,473,168	101,237,050	Jun 30 09:06 AM
LILLY ENDOWMENT INC	10% Owner	Jun 22 '23	Sale	459.28	107,022	49,153,574	101,248,810	Jun 23 11:27 AM
LILLY ENDOWMENT INC	10% Owner	Jun 21 '23	Sale	454.13	31,454	14,284,313	101,355,832	Jun 22 01:06 PM
LILLY ENDOWMENT INC	10% Owner	Jun 20 '23	Sale	454.08	34,156	15,509,556	101,387,286	Jun 21 03:13 PM
LILLY ENDOWMENT INC	10% Owner	Jun 16 '23	Sale	455.50	25,015	11,394,292	101,421,442	Jun 20 01:26 PM
LILLY ENDOWMENT INC	10% Owner	Jun 15 '23	Sale	454.15	27,353	12,422,248	101,446,457	Jun 16 03:58 PM
Norton Johna	EVP, Global Quality	Jun 15 '23	Sale	448.00	1,647	737,856	30,114	Jun 15 04:21 PM
Norton Johna	EVP, Global Quality	Jun 14 '23	Sale	444.29	1,647	731,746	31,761	Jun 15 04:21 PM
Rau Diogo	EVP & CIDO	Jun 01 '23	Option Exercise	0.00	6,300	0	10,694	Jun 02 04:44 PM
Jonsson Patrik	EVP&Pres, LLY Imm, LLY USA&CCO	Jun 01 '23	Sale	429.46	6,000	2,576,760	36,941	Jun 02 04:29 PM
LILLY ENDOWMENT INC	10% Owner	May 19 '23	Sale	442.62	194,354	86,024,241	101,473,810	May 22 12:01 PM
Zakrowski Donald A	SVP, Finance, & CAO	May 15 '23	Sale	435.29	600	261,174	5,978	May 16 04:31 PM
LILLY ENDOWMENT INC	10% Owner	May 12 '23	Sale	442.77	20,646	9,141,436	101,668,164	May 15 01:01 PM
LILLY ENDOWMENT INC	10% Owner	May 03 '23	Sale	426.40	178,302	76,028,738	101,688,810	May 04 02:30 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

FGEN

FibroGen Inc

LLY

Lilly(Eli) & Co

Upgrade your FINVIZ experience